Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer

Summary

This phase III trial compares the use of a digital chatbot enabled intervention to standard remote genetic services for increasing uptake of genetic counseling and testing among adolescents and young adult (AYA) cancer patients. Genetic testing for cancer predisposition syndromes has become standard evidence-based practice and can inform enhanced screening and risk reducing measures to reduce cancer morbidity and mortality. Despite this, many AYAs are not receiving recommended genetic counseling and testing. Offering remote telehealth services can address access barriers and chatbots and texting interventions could enhance patient outcomes and reduce provider and staff time. The use of a digital chatbot enabled intervention may be equally as effective as standard remote genetic services in AYA cancer patients undergoing genetic testing.

Conditions

• Miscellaneous Neoplasm, Nos
• Non-Neoplastic Condition, Nos

Interventions

OTHER

Telemedicine

Undergo telehealth visit with genetic counselor for pretest genetic education

OTHER

Genetic Testing

Complete standard of care genetic testing

OTHER

Telemedicine

Undergo telehealth visit with genetic counselor for disclosure of results

OTHER

Internet-Based Intervention

Receive access to Genetic Journey Chatbot

OTHER

Educational Intervention

Complete digital pre-test genetic education

BEHAVIORAL

Patient Navigation

Utilize chatbot to answer questions, assess barriers, and provide reminders for next steps during the testing period

OTHER

Interview

Complete interview

OTHER

Survey Administration

Ancillary studies

Sponsors & Collaborators

• National Cancer Institute (NCI)

  collaborator NIH

• Alliance for Clinical Trials in Oncology

  lead OTHER

Principal Investigators

• Angela Bradbury, MD · Alliance for Clinical Trials in Oncology

Study Design

Allocation

RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2025-12-10

Primary Completion

2028-04-28

Completion

2029-04-30

Countries

• United States

Study Locations